Transplant Trial Watch

Measurement properties of patient-reported outcome measures (PROMs) used in adult patients with chronic kidney disease: A systematic review.

Aiyegbusi OL, Kyte D, et al.

PLoS ONE 2017; 12(6): e0179733.

To inform the suitable selection of patient-reported outcome measures (PROMs) for monitoring the symptoms of chronic kidney disease (CKD) and its treatment effects in pre-dialysis, dialysis and renal transplant patients.

The databases MEDLINE, EMBASE, PsycINFO and CINAHL Plus were searched from inception to 21st December 2015 for studies that focused on PROMs used specifically for measuring health-related quality of life and/or CKD symptoms in any CKD population, and reported either the development or evaluation of one or more psychometric properties of a PROM. Titles and abstracts were screened independently by two reviewers, as well as full-texts obtained for studies potentially meeting the eligibility criteria.

66 papers were included in the final analysis.

PROMs and their measurement properties.

Not described

CET Conclusions
This systematic review aimed to evaluate which patient reported outcome measures (PROMS) are suitable in adults with chronic kidney disease. A comprehensive search identified 66 publications that evaluated 25 PROMS of which ten were assessed in renal transplant recipients. The methodological quality was evaluated by two reviewers using the COSMIN checklist, a validated tool to critically appraise studies of psychometric properties. The COSMIN definitions of measurement properties were used to indicate which properties were evaluated by the included studies and the level of evidence for each measurement property was graded as `strong', `moderate', `limited' `unknown' or `conflicting. Two of the ten PROMs evaluated in transplant recipients were generic (SF-36 and EQ-5D) whilst the other eight PROMS were disease specific. The End Stage Renal Disease-Symptom Checklist Transplantation Module (ESRD-SCLTM) scored best on the measurement properties and demonstrated strong evidence for internal consistency, moderate evidence for test-retest reliability, structural validity and hypothesis testing, and limited evidence for content validity in renal transplant recipients.

Quality notes
Quality assessment not appropriate

Trial registration
PROSPERO - CRD42016035554

Funding source
Non-industry funded